China considers mixing vaccines to bolster efficacy - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号)。如果该手机号尚未注册,将自动创建 FT中文网账号。短信可能需要几分钟送达,验证码15分钟内有效,请耐心等待:
请您阅读我们的用户注册协议和隐私权保护政策,点击下方按钮即视为您接受。
新型冠状病毒

China considers mixing vaccines to bolster efficacy

Disease control centre makes first public admission that there are efficacy problems with domestic jabs
00:00

{"text":[[{"start":13.61,"text":"The Chinese Center for Disease Control and Prevention has raised the prospect of mixing vaccines and varying doses to boost efficacy, the first time a government body has acknowledged concerns over the effectiveness of homegrown jabs. "}],[{"start":28.93,"text":"Gao Fu, CDC head, told a conference on Saturday that the agency was “considering how to solve the problem that the efficacy of existing vaccines is not high”, according to local media. "},{"start":40.984,"text":"Gao proposed mixing different vaccines as well as amending the sequence of doses, such as changing the number and quantity of doses, and the interval between them. "}],[{"start":51.739999999999995,"text":"Any new strategy will have ramifications for the more than 20 countries that China said it was supplying in mostly bilateral “vaccine diplomacy” deals. "}],[{"start":61.66,"text":"As of March, China had supplied 40m doses to countries across the globe, including Brazil, Serbia and the United Arab Emirates, prompting the US and its allies to launch their own drive to supply 1bn doses of Johnson & Johnson’s Covid-19 vaccine to south-east Asian nations. "}],[{"start":81.38,"text":"Chile, which has relied on China’s Sinovac vaccine for its inoculation campaign, is in the midst of another Covid-19 wave from new variants. "},{"start":90.984,"text":"The country has administered 62 doses per 100 residents, according to the Financial Times vaccine tracker, the third-highest rate in the world. "}],[{"start":100.88,"text":"A recent study of the effectiveness of Chile’s vaccination programme found the efficacy of a single dose of the Sinovac jab was just 3 per cent, compared with 56 per cent with two shots. "},{"start":113.109,"text":"However, local health experts have not linked the latest wave to the vaccine’s efficacy rate. "}],[{"start":120.19999999999999,"text":"Social-media posts on Gao’s remarks were swiftly censored, according to Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations. "}],[{"start":131.1,"text":"“It is the first time . . . a government official publicly admitted that the protection rate is a concern in the vaccination drive,” Huang added. "},{"start":139.47899999999998,"text":"China had administered 65m doses across the country by the middle of March. "}],[{"start":145.60999999999999,"text":"Unlike other vaccine producers, China’s manufacturers have not published their phase 3 trial data, leading to accusations of a lack of transparency over the vaccine’s effectiveness on different groups. "}],[{"start":158.85999999999999,"text":"For now, the main jabs approved for use in China are the traditional “inactivated virus” vaccines produced by Sinopharm, Sinovac and other domestic groups. "}],[{"start":169.94,"text":"Sinopharm claims a 79 per cent efficacy rate, similar to those achieved by AstraZeneca in its US trials. "},{"start":178.232,"text":"However, while AstraZeneca revised down its rates after facing criticism for releasing incomplete data, neither Sinopharm nor any of its Chinese peers have released phase 3 data for public scrutiny. "}],[{"start":193.07999999999998,"text":"Peter English, a retired communicable disease control consultant at Public Health England, said it was “astonishing” that phase 3 trial data for the Chinese vaccines had not yet been published. "}],[{"start":205.82999999999998,"text":"“We have little information on how effective these vaccines are,” he said, adding efficacy data against variants of concern was needed. "},{"start":214.68399999999997,"text":"Still, English said it was “interesting” that China was considering mixing and matching vaccines after moves from France and Germany to do so following safety concerns about the Oxford/AstraZeneca shot. "}],[{"start":227.89999999999998,"text":"Sinovac Biotech’s CoronaVac vaccine has an overall efficacy rate of 51 per cent among people aged between 18 and 60, according to documents published by a Hong Kong panel of experts. "}],[{"start":241.45999999999998,"text":"However, CoronaVac phase 1 and 2 data published in The Lancet found the shots were “safe and well tolerated”. "}],[{"start":249.89,"text":"Gao also warned that reopening China’s borders to foreigners, who have been barred from entering the country since March last year, posed a risk to elderly people, who have not yet been vaccinated. "}],[{"start":262.69,"text":"The timing of relaxing border restrictions will affect attendees at Beijing’s Winter Olympic Games in February 2022. "}],[{"start":271.6,"text":"Additional reporting by Donato Mancini in Rome "}],[{"start":275.12,"text":""}]],"url":"https://creatives.ftacademy.cn/album/001092107-1618190844.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

中国的通胀降温趋势是否已经根深蒂固?

9月通胀数据能否锁定美国今年剩余时间的利率政策?英国经济的韧性如何?

印度“蟑螂”领导人获释,运动呼吁举行更多抗议

青年主导的蟑螂人民党成员阿比吉特•迪普克获法院下令释放;警方则加强了新德里的安保。

紧张局势升级之际,美国在阿曼湾袭击一艘商用油轮

中央司令部称,该船试图突破美国对伊朗港口实施的海上封锁;这是美军一个月来的首次袭击。

亲欧盟团体主张:若政治立场一致,英国可在一届议会任期内重返欧盟

“英国最佳”表示,伦敦与欧盟保持一致将加快任何重新加入进程;安迪•伯纳姆正准备提出“选项”。

你的AI治疗师存在的问题

数百万人正求助于聊天机器人解决心理健康问题,但仅限于语言交流的科技无法治愈他们。

摩根大通押注欧洲资产管理业务增长

负责该行欧洲资产管理业务的帕特里克•汤姆森表示,他“看好英国”。
设置字号×
最小
较小
默认
较大
最大
分享×